Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Equus caballus hair is a biological allergenic extract derived from the hair of the domestic horse, used primarily for the diagnosis of horse-related allergies. Approved by the FDA in 1967, it is utilized in skin prick and intradermal testing to identify patients with IgE-mediated hypersensitivity to horse dander and hair proteins. The extract contains a variety of proteins, including the major allergen Equ c 1, which induce a localized allergic response (wheal and flare) in sensitized individuals. This diagnostic tool allows clinicians to confirm clinical sensitivity and guide management strategies, such as allergen avoidance or subcutaneous immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on equus caballus hair.